LLY

1,004

-0.33%↓

JNJ

226.76

-1.74%↓

ABBV

210.42

-0.19%↓

UNH

393.66

-1.34%↓

AZN

181.62

-1.79%↓

LLY

1,004

-0.33%↓

JNJ

226.76

-1.74%↓

ABBV

210.42

-0.19%↓

UNH

393.66

-1.34%↓

AZN

181.62

-1.79%↓

LLY

1,004

-0.33%↓

JNJ

226.76

-1.74%↓

ABBV

210.42

-0.19%↓

UNH

393.66

-1.34%↓

AZN

181.62

-1.79%↓

LLY

1,004

-0.33%↓

JNJ

226.76

-1.74%↓

ABBV

210.42

-0.19%↓

UNH

393.66

-1.34%↓

AZN

181.62

-1.79%↓

LLY

1,004

-0.33%↓

JNJ

226.76

-1.74%↓

ABBV

210.42

-0.19%↓

UNH

393.66

-1.34%↓

AZN

181.62

-1.79%↓

Home・Akcijų sąrašas・Hutchison China MediTech Ltd ADR

Hutchison China MediTech Ltd ADR

Uždarymo kaina

SektoriusSveikatos priežiūra

12.48 3.48

Pirkti Parduoti

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

12.45

Max

12.54

Pagrindiniai rodikliai
By Trading Economics
Pajamos	227M
Pardavimai	139M
P/E Sektoriaus vid.	4.857 51.415
Pelno marža	163.843
Darbuotojai	1,796
EBITDA	1.3M

Rekomendacijos
By TipRanks
Rekomendacijos	Pirkti
12 mėnesių prognozė	+57.85% upside

Rinkos statistika
By TradingEconomics
Rinkos kapitalizacija	2.2B
Ankstesnė atidarymo kaina	9
Ankstesnė uždarymo kaina	12.48

Naujienos nuotaikos

By Acuity

50%

155 / 345 reitingas Healthcare

Techninis įvertinimas

By Trading Central

Pasitikėjimas

Strong Bearish Evidence

14.24 / 14.78 Palaikymas ir pasipriešinimas

Hutchison China MediTech Ltd ADR Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2026-05-15 22:47; UTC

Karštos akcijos

Stocks to Watch: Macy's, Delta, UnitedHealth, NextNRG

2026-05-15 22:16; UTC

Įsigijimai, susijungimai, perėmimai

Canadian Tribunal Gives Keyera, Plains Until Late June to Rebut Bid to Undo Merger

2026-05-15 22:00; UTC

Pagrindinės rinkos jėgos

Delta Air Shares Rise as Berkshire Hathaway Discloses Stake

2026-05-15 18:09; UTC

Pagrindinės rinkos jėgos

Palo Alto Shares Head for Record-High Close, Analysts See Benefits to Identity Security Pivot

2026-05-15 16:02; UTC

Uždarbis

Pagrindinės rinkos jėgos

Forward Industries Shares Fall on New Debt as Solana Value Drops

2026-05-15 14:55; UTC

Pagrindinės rinkos jėgos

Aardvark Therapeutics Shares Plunge After FDA Hold on ARD-101 New Drug Application

2026-05-15 14:43; UTC

Pagrindinės rinkos jėgos

Chip Stocks Slide After U.S.-China Summit Ends Without Major Tech Deals -- Update

2026-05-15 22:17; UTC

Įsigijimai, susijungimai, perėmimai

Berkshire Boosted Stake in Alphabet in First Quarter, Bought Delta Air, Sold Visa, Mastercard -- Barrons.com

2026-05-15 21:59; UTC

Įsigijimai, susijungimai, perėmimai

Stanley Druckenmiller Just Exited Alphabet. TCI Fund Management Is Buying. -- Barrons.com

2026-05-15 21:50; UTC

Įsigijimai, susijungimai, perėmimai

Berkshire Boosted Stake in Alphabet in First Quarter, Bought Delta Air, Sold Visa, Mastercard -- Barrons.com

2026-05-15 21:30; UTC

Įsigijimai, susijungimai, perėmimai

Bill Ackman's Pershing Square Bets on Microsoft's AI Ambitions With New Stake -- 4th Update

2026-05-15 21:16; UTC

Rinkos pokalbiai

Canada Oil Producers Expect Govt Cash Before Building Pathways Project -- Market Talk

2026-05-15 20:50; UTC

Rinkos pokalbiai

Auto & Transport Roundup: Market Talk

2026-05-15 20:50; UTC

Rinkos pokalbiai

Basic Materials Roundup: Market Talk

2026-05-15 20:19; UTC

Karštos akcijos

Stocks to Watch Recap: Intel, Nvidia, Amgen, LVMH -- WSJ

2026-05-15 19:41; UTC

Įsigijimai, susijungimai, perėmimai

SanDisk Stock Is Up 494% This Year. Insiders Are Cashing In on the AI-Fueled Surge. -- Barrons.com

2026-05-15 19:35; UTC

Rinkos pokalbiai

Oil Futures Settle Higher on Inventory Worries -- Market Talk

2026-05-15 19:33; UTC

Rinkos pokalbiai

U.S. Natural Gas Futures Rise as Weather Heats Up -- Market Talk

2026-05-15 18:35; UTC

Uždarbis

Xanadu Quantum Revenue Increases Fourfold. Why the Stock Is Falling. -- Barrons.com

2026-05-15 17:28; UTC

Rinkos pokalbiai

U.S. Oil Rig Count Rises by 5 to 415 -- Market Talk

2026-05-15 16:50; UTC

Įsigijimai, susijungimai, perėmimai

Microsoft Stock Moves Higher After Ackman Announces New Stake -- WSJ

2026-05-15 16:24; UTC

Įsigijimai, susijungimai, perėmimai

Bill Ackman's Pershing Square Bets on Microsoft's AI Ambitions With New Stake -- 3rd Update

2026-05-15 16:20; UTC

Rinkos pokalbiai

Tech, Media & Telecom Roundup: Market Talk

2026-05-15 16:20; UTC

Rinkos pokalbiai

Auto & Transport Roundup: Market Talk

2026-05-15 16:20; UTC

Rinkos pokalbiai

Basic Materials Roundup: Market Talk

2026-05-15 15:55; UTC

Rinkos pokalbiai

Canada's 1Q Rebound Not a Turning Point -- Market Talk

2026-05-15 15:20; UTC

Rinkos pokalbiai

Global Forex and Fixed Income Roundup: Market Talk

2026-05-15 15:20; UTC

Rinkos pokalbiai

Silver Plunges on Inflation Worries -- Market Talk

2026-05-15 15:20; UTC

Uždarbis

A Micron and Sandisk Peer Is Coming to U.S. Markets. What to Know About Japan's Kioxia. -- Barrons.com

2026-05-15 14:33; UTC

Rinkos pokalbiai

Dollar Could Drift Higher as it Retains High-Yielding Status -- Market Talk

Akcijų palyginimas

Kainos pokytis

Hutchison China MediTech Ltd ADR Prognozė

Kainos tikslas

By TipRanks

57.85% į viršų

12 mėnesių prognozė

Vidutinis 20 USD 57.85%

Aukščiausias 20 USD

Žemiausias 20 USD

Remiantis 1 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Hutchison China MediTech Ltd ADR kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Pirkti

1 ratings

Pirkti

Laikyti

Parduoti

Remiantis 1 analitikų, pateikusių Hutchison China MediTech Ltd ADR akcijų reitingus – Dist per pastaruosius 3 mėnesius.

Techninis įvertinimas

By Trading Central

14.24 / 14.78Palaikymas ir pasipriešinimas

Recent bearish events outweigh bullish events.

All events are bearish.

Rinkos nuotaikos

By Acuity

155 / 345 reitingas Sveikatos priežiūra

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

Apie bendrovę Hutchison China MediTech Ltd ADR

HUTCHMED (China) Limited, together with its subsidiaries, discovers, develops, and commercializes targeted therapeutics and immunotherapies for cancer and immunological diseases in Hong Kong and internationally. The company develops Savolitinib for the treatment of non-small cell lung cancer (NSCLC), papillary renal cell carcinoma (RCC), and gastric cancer (GC); and Fruquintinib, an inhibitor for colorectal cancer (CRC), breast cancer, gastric cancer, microsatellite stable-CRC endometrial cancer (EMC), NSCLC, RCC, gastrointestinal, cervical, and solid tumors. It also develops Surufatinib, which is used for the treatment of pancreatic neuroendocrine tumor (NET), non-pancreatic NET, neuroendocrine carcinoma, SCLC, biliary tract cancer, and solid tumors; and Sovleplenib that treats hematological cancers and certain chronic immune diseases. In addition, it develops Tazemetostat for the treatment of certain epithelioid sarcoma and follicular lymphoma patients; HMPL-306, an inhibitor for hematological malignancies, gliomas, chondrosarcomas, cholangiocarcinomas, and solid tumors; HMPL-760, a Bruton's tyrosine kinase inhibitor; HMPL-453 for intrahepatic cholangiocarcinoma and solid tumors; HMPL-295 and HMPL-415 for solid tumors; HMPL-653 for metastatic solid tumors and tenosynovial giant cell tumors; and HMPL-A83 for the treatment of malignant neoplasms. It has collaboration agreements with AstraZeneca AB (publ), Lilly (Shanghai) Management Company Limited, Takeda, BeiGene Ltd., Inmagene Biopharmaceuticals Co. Ltd., Innovent Biologics Co., Inc., Genor Biopharma Co. Ltd., Shanghai Junshi Biosciences Co. Ltd., and Epizyme, Inc. The company was formerly known as Hutchison China MediTech Limited and changed its name to HUTCHMED (China) Limited in May 2021. HUTCHMED (China) Limited was incorporated in 2000 and is headquartered in Hong Kong, Hong Kong.